Annotated CRF

CI	M Pharmaceuticals, Inc.	₁ □	1 —	
	Subject ID 044	_ '	Ш	
	Subject Initials			
	INCLUS	Eligib	ility	
Inc	clusion Criteria (all answers must be YES to be included in the trial)	Yes	No	
1	Age 18-45 years, inclusive	🔲 1	□ 0	inc1
2	Willingness to submit to diagnostic machine testing	🔲 1	□ 0	inc2
3	Male or non-pregnant, non-lactating female. Women of reproductive potential must be practicing adequate contraception (e.g., intrauterine device or double barrier device such as diaphragm or condom plus spermicide). Abstinence is not considered to be an acceptable method of contraception. Additionally, women of reproductive potential must have a negative urine pregnancy at screening and prior to enrollment.)	o	inc3
4	In good health as determined by medical history and physical examinations	🔲 1	□ 0	inc4
5	Capable of understanding and complying with the protocol and has signed the informed consent document		По	inc5
Ex	EXCLUS clusion Criteria (all answers must be NO to be included in the trial)	Yes	L ∪ ∪ No	11100
1	Pregnant or lactating females	🔲 1	□ 0	exc1
2	History of anaphylaxis	🔲 1	□ 0	exc2
3	History or presence of hepatitis	🔲 1	□ 0	exc3

CM Pharmaceuticals, Inc.		Subject ID 044 - 1
		Subject Initials
		subjinit \$3 Demographics/Medical History
		Demograpmes/medical matery
DEMO		
Demographics		
Sex: sex \$1 Race: 1 Male	race \$9 asian r (specify):	₂ Black
Date of Birth:/ birthdt ////	у	Date Informed Consent Signed :/_icdt/
LABSDONE		
Pregnancy test Ibdsam		
Result:	∐ ₀ Negati	ve Ibdrescd 2 Not applicable
MEDHIST Medical History		
Medical History Body System	Normal	Abnormal (describe)
Neuro mhbodsys \$26	mhstatcd 0	mhterm \$200
HEENT	□ o	
Heart	□ o	
Lungs	□ o	
Abdomen	□ o	
Musculoskeletal	o	
Peripheral Vascular	o	
Skin	o	
Additional Findings:		mhafsp \$200

M Pharmaceutica	ls, Inc.		Sı	ubject ID 044 - 1
				Subject Initials
				Physical Examinat
PE				
		Study Day 1 peptm \$11		Study Day 2
Body System	Normal	Abnormal (describe)	Normal	Abnormal (describe)
Neurological pebodsys \$21	pestatcd 0	pefind \$160	О	pechgcd ☐ 1 Unchanged from Study Day 1
HEENT	□ o		□ o	☐ ₁ Unchanged from Study Day 1
Heart	□ o		О	☐ ₁ Unchanged from Study Day 1
Lungs	□ o		О	☐ 1 Unchanged from Study Day 1
Abdomen	□ o		□ o	☐ 1 Unchanged from Study Day 1
Musculoskeletal	o		О	☐ 1 Unchanged from Study Day 1
Peripheral Vascular	□ 0		О	☐ 1 Unchanged from Study Day 1
Skin	□ o		О	☐ 1 Unchanged from Study Day 1
Additional Findings:			□₄Uncha	nged from Study Day 1

CM Pharmaceuticals, Inc.	
	Subject ID 044 - 1
	Subject Initials
	Laboratory

LABS	Study Day 1	Study Day 2
Name of Lab	Ibnamecd Ibname \$50	
lbtest \$16 Lab test	Result	Result
	Ibstresn	
	☐ ₁ Not Done	☐ ₁ Not Done
Sodium		
Potassium		
Chloride		
BUN		
Creatinine		
Total Protein		
Albumin		
Direct bilirubin		
Total bilirubin		
ALT/SGPT		
AST/SGOT		
LDH		
WBC		
Neutrophils		
Eosinophils		
Basophils		
Lymphocytes		
Monocytes		
Hct%		
Hgb		
Platelets		
INR		
PT		
PTT		

CM F	Pharmaceutic	als, Inc.						Subject ID	0	44 - 1 🗌	
								Subject	Init	ials 🔲 🗌	
		;	Stuc	ly Day 1		 /y		Evaluation	on	s and Dos	sing
VI	TAL	1.01									
	Baseline Vita Time (24 Hour)	ai Signs Tem (%F)		HR (per minute)	RI (per mi		e)	BP (syst/dia)		O ₂ Sat (%)	
visit \$11	vsacttm :	temp		heart	resp			sysbp /diab	p	o2sat	
,	VITAL Weight					HQ:	SCC				_
	We	eight		Height			Hea	ılth Questioi	nna	ire Score	
	weight	veightun		height	un inches		mms	Pre mmptm core	\$24	Post	
EXPOS	URE			period							
'	Cohort			Infusion Period #1			Infusion Period # 2				
	coho	rt	modeco	^d mode Bottle 12.5 m	g/kg	☐ ₁ Bottle 12.5 mg/kg			g/kg		
	2 🗆		2	Bag 6.25 m	g/kg	☐ ₂ Bag 6.25 mg/kg			g/kg		
				Bag, other <u>0</u>							
			ļ.	Amount PROD in	nfused			Amount PR	OD	infused	
	□Other			proddose	mg		_	·		mg	

CM Pharmaceuticals, Inc.		Subject ID 044 - 1
		Subject Initials
	Study Day 1	Vital Signs
VITALTPT \$31		

VITALTPT \$31	- -	UB	P.5	0.0
Timepoint	Time (24 Hour)	HR (per min)	BP (syst/dia)	O ₂ Sat (%)
- 5 minutes	vsacttm :	heart	sysbp / diapb	o2sat
0 minutes	:		1	
5 minutes	:		1	
10 minutes	:		1	
15 minutes	:		1	
20 minutes	:		1	
25 minutes	:		1	
30 minutes	:		1	
35 minutes	:		1	
40 minutes	:		1	
45 minutes	:		1	
50 minutes	:		1	
55 minutes	:		1	
60 minutes	:		1	
65 minutes	:		1	
70 minutes	:		1	
End of Infusion Period #2	:			
1 hour after Infusion Period #2	:		1	

CM P	harmaceuticals, Inc.				Subject IE	044 - 1 🔲 🗀
					Subject	t Initials 🔲 🔲 🦳
		CONME	DS		Concomit	ant Medications
□ ₀ N	lone cmanycd					
	Medication	Dose	Unit	Route	Date (mm / dd / yy)	Time (24 Hour)
1	cmterm \$80	cmdose \$10	cmunit \$10	cmroute \$10	cmstdtc \$10	cmtm :
2	Coding: cmprefcd \$11 - \		Code		//	:
3	cmatccd \$5 - AT cmatc \$50 - ATC				/	:
4					/	:
5						:
6						:
7					//	:
8					//	:
9					//	:
10					//	:
11					/	:
12						:
					Check if	subsequent pages

СМ Г	Pharmaceuticals, Inc.							
		F		ıs Adverse Even DIATELY	its	Subject	id 044 - 1 🔲 🗌]
						Subje	ect Initials 🔲 🔲	
		AE					Adverse Event	s
□ o	None aeanycd							
	Event Description		Onset	Resolution	Severity	Relationship to PROD	Actions taken (✓ all applicable)	
1	aeterm \$120	Date (mm/dd/yy) Time (24 hour)	aestdt aesttm	aeendt aeentm : Continuing	☐ 1 Mild ☐ 2 Moderate ☐ 3 Severe ☐ 4 Life-threatening aesevcd	☐ 1 Unrelated ☐ 2 Possibly ☐ 3 Probably ☐ 4 Definitely aerelcd	☐ None aenoatcd ☐ Treatment aetxcd ☐ PROD stopped ← ☐ 3 Discontinued trial← ☐ SAE Reported←	aeprencd –aedccd - aeserc
2		Date (mm/dd/yy) Time (24 hour)	/:	aeongocd : : : : : : : : : : : : : : : : : : :	☐ 1 Mild ☐ 2 Moderate ☐ 3 Severe ☐ 4 Life-threatening	☐ 1 Unrelated ☐ 2 Possibly ☐ 3 Probably ☐ 4 Definitely	☐ None ☐ Treatment ☐ PROD stopped ☐ Discontinued trial ☐ SAE Reported	
3		Date (mm/dd/yy) Time (24 hour)	/:	/	☐ 1 Mild ☐ 2 Moderate ☐ 3 Severe ☐ 4 Life-threatening	☐ 1 Unrelated ☐ 2 Possibly ☐ 3 Probably ☐ 4 Definitely	☐ None ☐ Treatment ☐ PROD stopped ☐ Discontinued trial ☐ SAE Reported	
4		Date (mm/dd/yy) Time (24 hour)	/:		☐ 1 Mild ☐ 2 Moderate ☐ 3 Severe ☐ 4 Life-threatening	☐ 1 Unrelated ☐ 2 Possibly ☐ 3 Probably ☐ 4 Definitely	☐ None ☐ Treatment ☐ PROD stopped ☐ Discontinued trial ☐ SAE Reported	
		Cod	ding: aeprefcd \$8 -				·	
			•) - Medra Preferred T	erm			
lnv	estigator's Signature		aesoccd \$8 - 9 aesoc \$100 -			Date ☐₁ Check if su	bsequent pages	

	Stud	dy Day 2	mm dd	Subject Initial Study (
Study Completio	n/Termination	n VITAL			
Vital Signs Time	Temp	HR	RR	BP	O ₂ S
(24 Hour)	(°F)	(per minute)	(per minute	e) (syst/dia)	(%
i Did the subject co f No, please comp			/es □₀No cable) DISPOSI	dsstatcd	
Reason for disco	ontinuation	Date	2101 001		
☐₁ Adverse Ever	-	mm / dd / yy / /	event:	dsaesp \$140	
dsa	nsent	dsaedt / /	reason:	dswdsp \$40	
dsw	/dcd	dswddt	-	·	
Lost to follow delo	up ostcd	dslostdt reason:		dslostsp \$140	
☐₄ Blood clot	-tl	//	_		
dsclo	otca	dsshntdt / /	specify:	dsothsp \$200	
<u> </u>	thcd	dsothdt			
Summary of Prot Was the protocol f	•		☐ ₁ Yes	☐ ₀ No departcd	
f No, please comp	lete the follow	ing (√ all applic	cable) SUMMA	RY	
	rtures				
☐ ₁ Entrance Crit	eria not met	specify:	r	reassp1 \$200	
2 PROD not ac	dministered ful	ly reason:	ľ	eassp2 \$200	
☐₃ Images not o	btained	explain:			
	ot obtained or r	not			
	cheduled time p				
□ ₅ Other		specify:			
		<u>'</u>			